ESR1 and breast carcinoma: As the first line of endocrine therapy, estrogen receptor positive (ER+) breast cancers were treated with Tamoxifen (TAM) (1,2), although low efficacy of this drug for treatment of ER-negative (ER) is still a crucial challenge (3).